Printer Friendly

/C O R R E C T I O N -- ISIS PHARMACEUTICALS/

 In NY087, "ISIS PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF TWO MILLION FIVE HUNDRED THOUSAND SHARES OF COMMON STOCK," moved earlier today, we are advised by a representative of the company that the first graph, fifth line, should read..."over-allotment option for three hundred seventy-five thousand shares," sted of..."over-allotment option for two million eight hundred seventy-five thousand shares" as origianlly issued.
 -0- 1/20/93 C NY087
 /PRNewswire -- Jan. 20/


CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU: OFR

LD-TM -- NY087X -- 7176 01/20/93 20:47 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 20, 1993
Words:88
Previous Article:UNITED FEDERAL BANCORP RECORDS 19.4 PERCENT INCREASE IN 1992 NET INCOME
Next Article:STANLEY H. KATZ
Topics:


Related Articles
ISIS PHARMACEUTICALS FILES PUBLIC OFFERING FOR 2 MILLION SHARES OF COMMON STOCK
ISIS ANNOUNCES MANUFACTURING COLLABORATION WITH MILLIPORE
ISIS ANNOUNCES MANUFACTURING COLLABORATION WITH MILLIPORE
ISIS COMPLETES NORMAL SUBJECT STUDY AND INITIATES TRIALS IN PATIENTS WITH ITS FIRST ANTISENSE DRUG
ISIS PHARMACEUTICALS BEGINS PHASE II TRIALS ON ISIS 2105 FOR GENITAL WARTS
ISIS PHARMACEUTICALS AND EISAI AGREE TO CODEVELOP ANTISENSE DRUG
SPI PHARMACEUTICALS ANNOUNCES SECOND QUARTER DIVIDEND
Isis Pharmaceuticals Highlights New GeneTrove Functional Genomics Division At CS First Boston West Coast Biotechnology Field Trip.
Isis Pharmaceuticals Licenses Antisense Anti-Cancer Drug to Sarissa.
Patients With HIV-Associated Wasting Gain More Weight With Concentrated Form of Megestrol Acetate, Study Shows.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters